We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva’s Neupogen ‘Biosimilar’ Will Likely Take Half of Market by 2016: Analyst
Teva’s Neupogen ‘Biosimilar’ Will Likely Take Half of Market by 2016: Analyst
August 30, 2012
Teva has scored a victory on the road to biosimilar approvals with the FDA’s OK of its copycat version of Amgen’s Neupogen, a win that could halve Amgen’s U.S. market share by the end of 2016, analysts say.